← Back to headlines
Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate
Amgen Inc. (AMGN) announced today the successful completion of its Phase 3 clinical trial for ABP 206, a biosimilar candidate for Opdivo. The trial evaluated the safety and efficacy of ABP 206 in patients with advanced melanoma. Results from the trial are expected to be presented at an upcoming medical conference.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
